이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Universal Biosensors 미래 성장

Future 기준 확인 0/6

현재 Universal Biosensors 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Medical Equipment 수익 성장	15.7%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Universal Biosensors 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

ASX:UBI - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	7	-6	-16	-15	N/A
12/31/2023	7	-7	-16	-15	N/A
9/30/2023	5	-18	-11	-10	N/A
6/30/2023	4	-20	-17	-15	N/A
3/31/2023	4	-26	-17	-15	N/A
12/31/2022	5	-27	-16	-15	N/A
9/30/2022	5	-19	-16	-14	N/A
6/30/2022	5	-16	-15	-14	N/A
3/31/2022	6	-14	-13	-12	N/A
12/31/2021	6	-11	-11	-10	N/A
9/30/2021	6	-7	-10	-9	N/A
6/30/2021	6	-6	-9	-9	N/A
3/31/2021	4	-8	-9	-8	N/A
12/31/2020	3	-8	-9	-8	N/A
9/30/2020	3	-7	-16	-6	N/A
6/30/2020	4	-6	-20	-10	N/A
3/31/2020	6	-4	-20	-10	N/A
12/31/2019	7	-5	23	33	N/A
9/30/2019	14	-8	31	31	N/A
6/30/2019	60	35	39	39	N/A
3/31/2019	64	35	42	42	N/A
12/31/2018	69	38	1	2	N/A
9/30/2018	65	39	7	7	N/A
6/30/2018	24	-4	7	8	N/A
3/31/2018	25	-3	8	9	N/A
12/31/2017	25	-1	N/A	9	N/A
9/30/2017	26	6	N/A	1	N/A
6/30/2017	23	5	N/A	9	N/A
3/31/2017	22	5	N/A	8	N/A
12/31/2016	19	1	N/A	7	N/A
9/30/2016	17	-6	N/A	6	N/A
6/30/2016	20	-4	N/A	3	N/A
3/31/2016	19	-5	N/A	-2	N/A
12/31/2015	17	-7	N/A	-1	N/A
9/30/2015	18	-5	N/A	-4	N/A
6/30/2015	14	-6	N/A	-6	N/A
3/31/2015	11	-9	N/A	-5	N/A
12/31/2014	10	-9	N/A	-7	N/A
9/30/2014	8	-12	N/A	-8	N/A
6/30/2014	8	-11	N/A	-16	N/A
3/31/2014	12	-11	N/A	-16	N/A
12/31/2013	15	-12	N/A	-17	N/A
9/30/2013	18	-13	N/A	-13	N/A

애널리스트 미래 성장 예측

수입 대 저축률: UBI 의 예상 수익 증가율이 절약률( 2.3% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: UBI 의 수익이 Australian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: UBI 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: UBI 의 수익이 Australian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: UBI 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: UBI 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Universal Biosensors 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target increased to AU$1.15

Price target increased to AU$1.15

Consensus revenue estimates fall by 19%

Consensus revenue estimates fall by 10%

Price target increased to AU$1.25

Forecast to breakeven in 2024

Recent updates

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

New minor risk - Shareholder dilution

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 10 million.

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022)

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022)

New minor risk - Share price stability

First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022)

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Full year 2022 earnings: EPS and revenues miss analyst expectations

Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia

Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA

Universal Biosensors, Inc. Announces Chairman Changes

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Non-Executive Chairman recently bought AU$54k worth of stock

Price target increased to AU$1.15

Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021)

Price target increased to AU$1.15

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Non-Executive Chairman recently bought AU$56k worth of stock

Consensus revenue estimates fall by 19%

Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021)

Consensus revenue estimates fall by 10%

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.

First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021)

Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Price target increased to AU$1.25

Forecast to breakeven in 2024

Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market

Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020)

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020)

Independent Non-Executive Director has left the company

Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director

Full year 2020 earnings released: AU$0.043 loss per share (vs AU$0.027 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

New 90-day high: AU$0.54

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Universal Biosensors, Inc. Releases SENTIA

New 90-day high: AU$0.34

Independent Non-Executive Director recently bought AU$62k worth of stock

Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic

New 90-day high - AU$0.33

New 90-day high - AU$0.27

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견